MAP2K7 and melanoma: In patients with stage IV melanoma, immune checkpoint inhibitors are the preferred first-line treatment regardless of BRAF mutational status, and advanced melanoma patients carrying BRAF V600 mutation can also benefit from BRAF + MEK inhibitor treatment in certain cases [4].